Tag: CDK4/6 Inhibitors
The on-demand video of the webinar “CDK4/6 Inhibition in Early and Advanced Breast Cancer – Recent data and controversies 2024“ is now available!
14.11.2024
The virtual continuing education event “CDK4/6 Inhibition in Early and Advanced Breast Cancer – Recent Data and Controversies 2024” took place on Wednesday, October 30th, 2024, from 5:30 to 7:30 pm CET. A total of 116 participants from 15 countries joined the webinar, which was moderated by ABCSG President Michael Gnant.
read more
The on-demand video of the webinar “CDK4/6 inhibition in early breast cancer – Recent data and controversies?” is now available!
22.11.2023
The virtual continuing education event “CDK4/6 inhibition in early breast cancer – Recent data and controversies?” took place on Wednesday, November 8th, 2023 (05:30 – 07:00 pm, CET). A total of 104 participants from 13 countries participated in the webinar.
read more
SAVE THE DATE:
CDK4/6 inhibition in early breast cancer – Recent data and controversies?
29.08.2023
| Date | 08.11.2023 |
| Location: | virtual |
In this international ABCSG webinar that is co-sponsored by EliLilly and Novartis we will present and discuss the most recent data of the pivotal adjuvant CDK4/6 studies monarchE and NATALEE.
read more
Paradigm shift: a changing CDK4/6 inhibitor treatment landscape – NOW ONLINE!
12.07.2023
| Date | 14.09.2023 |
| Location: | virtual |
Cyclin-dependent kinase (CDK) 4/6 inhibitors have proven to be game changer as targeted cancer therapy of patients with hormone receptor-positive breast cancer and they have established as standard of care for the treatment of advanced HR+ breast cancer. Also, mechanisms of resistance to CDK4/6 inhibitors, biomarker analyses to better select patients who derive the greatest benefit from CDK4/6 inhibitors, in both early and advanced settings, and more issues have been elucidated.
read moreShare on